Table 1. Baseline characteristics in NSTE-ACS patients.
| Total (n=2,012) | De-escalation (n=997) | Conventional (n=1,015) | p value | ||
|---|---|---|---|---|---|
| Age | 59.3±8.9 | 59.1±8.9 | 59.5±8.8 | 0.313 | |
| Age ≥75 | 2 (0.1) | 2 (0.2) | 0 (0) | 0.245 | |
| Age ≥65 | 644 (32.0) | 312 (31.3) | 332 (32.7) | 0.496 | |
| Male | 1,788 (88.9) | 889 (89.2) | 899 (88.6) | 0.671 | |
| Body mass index | 25.8±2.8 | 25.7±2.8 | 25.9±2.9 | 0.313 | |
| Left ventricular ejection fraction | 60.5±9.1 | 60.7±8.8 | 60.3±9.5 | 0.392 | |
| Hypertension | 1,294 (64.3) | 641 (64.4) | 653 (64.3) | 0.992 | |
| Diabetes mellitus | 835 (41.5) | 425 (42.6) | 410 (40.4) | 0.309 | |
| Dyslipidemia | 1,553 (77.2) | 772 (77.4) | 781 (76.9) | 0.795 | |
| Chronic kidney disease | 55 (2.7) | 25 (2.5) | 30 (3.0) | 0.538 | |
| Peripheral artery disease | 24 (1.2) | 16 (1.6) | 8 (0.8) | 0.092 | |
| Smoking status | 0.340 | ||||
| Never smoker | 896 (44.5) | 434 (43.5) | 462 (45.5) | ||
| Current smoker | 653 (32.5) | 339 (34.0) | 314 (30.9) | ||
| Ex-smoker | 463 (23.0) | 224 (22.5) | 239 (23.5) | ||
| Previous myocardial infarction | 76 (3.8) | 29 (2.9) | 47 (4.6) | 0.043 | |
| Previous PCI | 233 (11.6) | 99 (9.9) | 134 (13.2) | 0.022 | |
| Previous CABG | 19 (0.9) | 10 (1.0) | 9 (0.9) | 0.787 | |
| Previous cerebrovascular accident | 28 (1.4) | 14 (1.4) | 14 (1.4) | 0.962 | |
| Family history of CAD | 148 (7.4) | 67 (6.7) | 81 (8.0) | 0.279 | |
| Non ST-elevation myocardial infarction | 591 (29.4) | 308 (30.9) | 283 (27.9) | 0.138 | |
| Medication at discharge | |||||
| Aspirin | 1,984 (99.3) | 980 (99.0) | 1,004 (99.5) | 0.267 | |
| Clopidogrel | 160 (8.0) | 79 (8.0) | 81 (8.0) | 0.974 | |
| Prasugrel | 1,847 (92.4) | 916 (92.6) | 931 (92.3) | 0.768 | |
| BB | 1,033 (51.8) | 520 (52.6) | 513 (51.0) | 0.464 | |
| ACEI | 1,107 (55.6) | 567 (57.4) | 540 (53.7) | 0.095 | |
| Statin | 1,888 (94.7) | 941 (95.2) | 947 (94.1) | 0.270 | |
| CCB | 479 (24.0) | 258 (26.1) | 221 (22.0) | 0.031 | |
| Lab | |||||
| Hb | 14.4±1.6 | 14.4±1.6 | 14.4±1.6 | 0.927 | |
| Plt | 230.5±57.7 | 230.9±57.4 | 230.1±57.9 | 0.768 | |
| BUN | 16.5±8.7 | 16.7±10.0 | 16.4±7.2 | 0.361 | |
| Creatinine | 1.0±1.0 | 1.1±1.0 | 1.0±0.9 | 0.501 | |
| Total cholesterol | 172.7±44.6 | 173.4±45.3 | 172.2±43.8 | 0.564 | |
| LDL | 103.9±38.5 | 104.4±38.8 | 103.5±38.2 | 0.661 | |
| HDL | 43.3±10.8 | 43.2±10.9 | 43.4±10.7 | 0.594 | |
| TG | 155.6±109.7 | 156.7±4.0 | 154.5±101.5 | 0.671 | |
| Number of diseased vessels | 0.127 | ||||
| One vessel | 988/2,000 (49.4) | 500/992 (50.4) | 488/1,008 (48.4) | ||
| Two vessel | 598/2,000 (29.9) | 305/992 (30.7) | 293/1,008 (29.1) | ||
| Three vessel | 414/2,000 (20.7) | 187/992 (18.9) | 227/1,008 (22.5) | ||
| Multivessel disease | 1012/2,000 (50.6) | 492/992 (49.6) | 520/1,008 (51.6) | 0.373 | |
| Anticoagulant agent for PCI | |||||
| Unfractionated heparin | 385/2,012 (19.1) | 182/997 (18.3) | 203/1,015 (20.0) | 0.320 | |
| Enoxaparin | 151/2,012 (7.5) | 83/997 (8.3) | 68/1,015 (6.7) | 0.166 | |
| Glycoprotein IIb/IIIa inhibitor | |||||
| Abciximab | 9/2,012 (0.4) | 4/997 (0.4) | 5/1,015 (0.5) | 1.000 | |
| Tirofiban | 0/2,012 (0) | 0/997 (0) | 0/1,015 (0) | - | |
| Lesion complexity | |||||
| Multi-lesion intervention | 595/1,987 (29.9) | 289/986 (29.3) | 306/1,001 (30.6) | 0.540 | |
| Heavy calcification | 267/1,977 (13.5) | 123/977 (12.6) | 144/1,000 (14.4) | 0.239 | |
| Bifurcation lesion | 420/1,973 (21.3) | 211/976 (21.6) | 209/997 (21.0) | 0.722 | |
| Thrombotic lesion | 159/1,977 (8.0) | 84/977 (8.6) | 75/1,000 (7.5) | 0.370 | |
| ACC/AHA type B2/C lesion | 1,071/1,974 (54.3) | 539/975 (55.3) | 532/999 (53.3) | 0.366 | |
| In-stent restenosis lesion | 54/1,976 (2.7) | 27/977 (2.8) | 27/999 (2.7) | 0.934 | |
| IVUS use | 685/1,981 (34.6) | 337/981 (34.4) | 348/1,000 (34.8) | 0.834 | |
| Stent type | 0.723 | ||||
| Durable polymer-DES | 1,013/2,012 (50.3) | 498/997 (49.9) | 515/1,015 (50.7) | ||
| Absorbable polymer-DES | 999/2,012 (49.7) | 499/997 (50.1) | 500/1,015 (49.3) | ||
| Treated lesion number per person | 1.4±0.7 | 1.4±0.7 | 1.4±0.7 | 0.652 | |
| Stent number per person | 1.6±1.1 | 1.7±1.1 | 1.6±1.0 | 0.326 | |
| Total stent length (mm) | 42±31.4 | 42.2±32.8 | 41.8±30.0 | 0.775 | |
| Procedure success | 1,970/1,984 (99.3) | 975/984 (99.1) | 995/1,000 (99.5) | 0.270 | |
Values are presented as mean ± standard deviation or number (%).
ACC/AHA = American College of Cardiology/American Heart Association; ACEI = angiotensin-converting-enzyme inhibitor; BB = beta blocker; BUN = blood urea nitrogen; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CCB = Calcium channel blocker; DES = drug-eluting stent; HDL = high density lipoprotein; Hb = hemoglobin; IVUS = intravascular ultrasound; LDL = low density lipoprotein; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; Plt = platelet; TG = triglyceride.